However, in the above investigations, most patients had received prior treatment, including systemic chemotherapeutic agents, and there were no data on EGFR mutations or treatment with EGFR-TKIs that strongly influenced the survival of patients with non-squamous NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.